The Experts below are selected from a list of 7635 Experts worldwide ranked by ideXlab platform
Flavio Ribichini - One of the best experts on this subject based on the ideXlab platform.
-
Transcatheter Valve-in-Mitral Homograft in Tricuspid Position: First-in-Human Report.
The Canadian journal of cardiology, 2020Co-Authors: Michele Pighi, Gabriele Pesarini, Mara Pilati, Concetta Mammone, Leonardo Gottin, Giovanni Battista Luciani, Fausto Castriota, Flavio RibichiniAbstract:A young woman with concomitant symptomatic severe stenosis and regurgitation was managed by Percutaneous Valve implantation because of a failing mitral homograft in the tricuspid position. The implant procedure was performed using an Edwards S3 23-mm Valve. Good hemodynamic results were achieved, and, at intermediate follow-up, she did not require hospitalization and was free of symptoms.
-
Transcatheter Valve-in-Mitral Homograft in Tricuspid Position: First-in-Human Report.
Canadian Journal of Cardiology, 2020Co-Authors: Michele Pighi, Gabriele Pesarini, Mara Pilati, Concetta Mammone, Leonardo Gottin, Giovanni Battista Luciani, Fausto Castriota, Flavio RibichiniAbstract:Abstract A young female characterized by concomitant symptomatic severe stenosis and regurgitation was managed by Percutaneous Valve implantation due to a failing mitral homograft in tricuspid position, using an Edwards S3 23mm Valve, with good hemodynamic results and intermediate follow-up free from hospitalization and symptoms.
-
Transcatheter Tricuspid Valve Implantation by Femoral Approach in Trivalvular Heart Disease
The American journal of cardiology, 2013Co-Authors: Flavio Ribichini, Giuseppe Faggian, Gabriele Pesarini, Mauro Feola, Marco Agostini, Gionata Molinari, Andrea Rossi, Corrado VassanelliAbstract:A man with severe rheumatic trivalvular disease was treated with surgical implantation of mechanical aortic and mitral prostheses at the age of 30 years and tricuspid bioprosthesis at the age of 50 years. At 61 years of age, he developed severe symptomatic tricuspid regurgitation due to bioprosthesis degeneration and was judged at very high risk for a third surgical approach. The investigators describe the successful transfemoral positioning of a 29-mm Edwards SAPIEN XT Percutaneous Valve inside the degenerated tricuspid prosthesis, with excellent acute results and no major complications. In conclusion, Percutaneous Valve-in-Valve treatment of degenerated bioprostheses is feasible by the transfemoral route and may be of assistance in very selected patients at high surgical risk.
John G. Webb - One of the best experts on this subject based on the ideXlab platform.
-
A New Transcatheter Aortic Valve and Percutaneous Valve Delivery System
Journal of the American College of Cardiology, 2009Co-Authors: John G. Webb, Lukas Altwegg, Jean-bernard Masson, Saad Al Bugami, Abdullah Al Ali, Robert A. BooneAbstract:Objectives: We describe procedural and clinical outcomes in a high-risk cohort undergoing transcatheter aortic Valve replacement with early next-generation transcatheter Valve and delivery systems....
-
Percutaneous aortic Valve replacement will become a common treatment for aortic Valve disease.
JACC. Cardiovascular interventions, 2008Co-Authors: John G. WebbAbstract:Percutaneous Valve replacement is developing into an effective and reproducible therapy for aortic Valve stenosis. Initial experience suggests that outcomes compare favorably with conventional Valve surgery in selected patients with comorbidities, such as advanced age. Caution is prudent, however, in the future a more mature procedure might represent a viable alternative for a much broader range of patients.
-
Percutaneous Valve procedures: an update.
Current problems in cardiology, 2008Co-Authors: Laurens F. Tops, Samir R. Kapadia, John G. Webb, E. Murat Tuzcu, Alec Vahanian, Ottavio Alfieri, Jeroen J. BaxAbstract:Valvular heart disease is an important cause of morbidity and mortality. Aortic stenosis and mitral regurgitation account for the majority of patients with native Valve disease. Although surgical treatment provides satisfactory outcome, a large proportion of patients do not undergo a surgical intervention, because of the high estimated operative risk and multiple comorbidities. Recently, new techniques that enable Percutaneous treatment of valvular heart disease have been developed and their feasibility has been reported in several studies. All techniques target a minimal invasive procedure with a low risk of procedure-related complications. In this article, an overview of the various Percutaneous procedures for mitral and aortic Valve disease is provided. In addition, an update on the ongoing trials in Percutaneous Valve procedures is presented. Finally, the role of imaging in performing Percutaneous Valve procedures will be discussed.
-
Percutaneous Valve repair and replacement techniques
Heart (British Cardiac Society), 2005Co-Authors: Brad Munt, John G. WebbAbstract:Valvular heart disease is a significant cause of morbidity and mortality. Rates increase with age and the prevalence will increase as the population ages. Several factors have led to an interest in expanding Percutaneous Valve repair and replacement techniques to more lesions in more patients. This review explores current Percutaneous Valve repair and replacement techniques in mitral stenosis, mitral regurgitation, aortic stenosis and aortic regurgitation in adults, outlines the future directions, and discusses some technique-related issues.
Ted Feldman - One of the best experts on this subject based on the ideXlab platform.
-
Prospects for Percutaneous Valve Therapies
Circulation, 2007Co-Authors: Ted Feldman, Martin B. LeonAbstract:Developmental efforts to achieve Percutaneous catheter-based therapies for cardiac Valve repair and replacement have advanced rapidly over the past several years. A variety of methods to treat mitral regurgitation (MR) and to replace aortic and pulmonic Valves have already been successfully employed in patients. These innovative clinical transcatheter Valve therapies were anticipated more than a decade ago by creative experimentalists who helped develop predicate techniques in animal models. For example, in 1992, a catheter-delivered ball-in-cage prosthetic aortic Valve was implanted in a canine model by Pavcnik1 and a stent-mounted bioprosthetic Valve was placed by Andersen, who used a retrograde transarterial approach in a swine model.2 Clearly, the catheter-based technologies used in clinical studies today in patients with aortic stenosis were derived from the fusion of known successful aortic Valve replacement (AVR) surgical devices and adaptive interventional modalities, first studied in experimental animal models. Similarly, approaches for transcatheter treatment of MR have also borrowed heavily from preexisting and accepted surgical techniques, such as the edge-to-edge leaflet coaptation technique and reduction ring mitral annuloplasty.3 Importantly, recognition that the coronary sinus parallels the mitral annulus has spurred unique catheter-based transvenous approaches to treat MR by indirectly reducing mitral annular dimensions.4 Because many of the new Percutaneous approaches to Valve therapy have been developed by surgeons, a collaboration has emerged between thoughtful surgeons and interventionalists, combining skill sets and experiences to accelerate the developmental pathways of less-invasive transcatheter Valve therapies. Growing recognition exists that Percutaneous alternatives to surgical therapies are required in some patient subgroups with valvular heart disease. Among patients with either mitral and/or aortic Valve disease, an expanding population of elderly patients with significant comorbidities may benefit from traditional surgical methods, but these methods are associated with unacceptable perioperative mortality or prolonged postoperative recoveries. In the EuroHeart Survey …
-
Percutaneous Valve Repair and Replacement Challenges Encountered, Challenges Met, Challenges Ahead
Circulation, 2006Co-Authors: Ted FeldmanAbstract:This issue of Circulation contains reports on the acute results of 2 approaches for Percutaneous heart Valve treatment.1,2 The introduction of nonsurgical, catheter-based approaches to the management of valvular heart disease is in a phase of rapid development. These 2 reports highlight both challenges and successes in phase I experience with these innovative therapies. Articles pp 842 and 851 Percutaneous Valve therapy developed initially with aortic Valve replacement, described by Andersen et al3 in 1992 in a swine model. These investigators fabricated a stent-mounted bioprosthetic Valve and demonstrated that Percutaneous implantation is feasible. Bonhoeffer et al4 reported the use of a stent-mounted bioprosthesis for pulmonic Valve replacement in 2000. This achievement clearly marked the beginning of the era of Percutaneous Valve replacement therapy in patients. Pulmonic Valve replacement with this Percutaneous approach has been remarkably successful. To date, >100 patients have been treated, with only a single procedure-related mortality and good results in a population of pediatric patients with congenital heart disease who otherwise would face third or fourth open heart procedures. Percutaneous aortic Valve replacement with a stent-mounted bioprosthetic Valve device was initially reported by Cribier et al5,6 in 2002, with a growing experience since then. Numerous technical and clinical challenges have been encountered during phase I procedures for Percutaneous heart Valve therapy. The patient population for aortic Valve replacement has been a group of patients considered high risk for surgery or nonsurgical candidates with numerous comorbid conditions. These patients have come to the cardiac catheterization laboratory with hypotension and low cardiac output. Under the best circumstances, they represent a great management challenge, even without the demands of new, complex Percutaneous procedures. Early mortality in this group has been high, but there have also been stunning successes. Percutaneous aortic Valve replacement was initially accomplished by …
-
Percutaneous treatment of valvular heart disease: catheter-based aortic Valve replacement and mitral Valve repair therapies.
The American journal of geriatric cardiology, 2006Co-Authors: Ted Feldman, Howard C. Herrmann, Fred G. St. GoarAbstract:Until recently, Percutaneous catheter therapy for valvular heart disease was limited to catheter balloon valvuloplasty for aortic, mitral, or pulmonic stenosis. A number of new approaches to Percutaneous Valve therapy are now developing rapidly, including methods for catheter-based Valve replacement and repair. Stent-mounted Valve prostheses have been successfully implanted in the pulmonic and aortic positions. These devices have been constructed using pericardial Valve leaflets mounted inside balloon-expandable or self-expanding stents and have been used in patients who are high risk for Valve replacement surgery. Percutaneous Valve repair is also being developed for mitral regurgitation. Direct leaflet repair and Percutaneous annuloplasty are being employed in clinical trials. All the Percutaneous approaches are based on existing surgical techniques and offer less invasive alternatives. The era of Percutaneous Valve therapy has clearly arrived, and ongoing trials will define the clinical role for these new therapies.
Peter C. Block - One of the best experts on this subject based on the ideXlab platform.
-
State of the art Percutaneous intervention for the treatment of valvular heart disease: a review of the current technologies and ongoing research in the field of Percutaneous Valve replacement and repair.
Cardiology, 2006Co-Authors: Vasilis C. Babaliaros, Peter C. BlockAbstract:Technical developments in valvular intervention culminated in the first Percutaneous Valve replacement in the pulmonary position (2000) followed by replacement in the aortic position (2002). More rece
-
Percutaneous Valve repair and replacement: the frontier of Valve disease treatment.
Future cardiology, 2005Co-Authors: Peter C. BlockAbstract:The Percutaneous treatment of mitral stenosis using balloon valvuloplasty is a reality. However, in Western countries there is only a low incidence of rheumatic valvular disease. Thus, attention is now focused on Percutaneous, transcatheter approaches that will allow wider ranging treatment of pulmonic, aortic and mitral Valve disease. These new approaches should result in Percutaneous technologies that will allow replacement of pulmonic and aortic Valves for both stenosis and regurgitation, repair of mitral regurgitation, and possibly even replacement of the mitral Valve. Pulmonic and aortic Valve replacement are already being studied in safety and efficacy trials in Europe. Investigators using Percutaneous mitral Valve repair will soon complete a Phase I US trial and the technology will be studied in a Phase II randomized trial. Patient care options for valvular heart disease are rapidly changing.‘Potential Percutaneous replacement of the mitral Valve still faces many practical hurdles, but sooner or la...
Howard C. Herrmann - One of the best experts on this subject based on the ideXlab platform.
-
Percutaneous treatment of valvular heart disease: catheter-based aortic Valve replacement and mitral Valve repair therapies.
The American journal of geriatric cardiology, 2006Co-Authors: Ted Feldman, Howard C. Herrmann, Fred G. St. GoarAbstract:Until recently, Percutaneous catheter therapy for valvular heart disease was limited to catheter balloon valvuloplasty for aortic, mitral, or pulmonic stenosis. A number of new approaches to Percutaneous Valve therapy are now developing rapidly, including methods for catheter-based Valve replacement and repair. Stent-mounted Valve prostheses have been successfully implanted in the pulmonic and aortic positions. These devices have been constructed using pericardial Valve leaflets mounted inside balloon-expandable or self-expanding stents and have been used in patients who are high risk for Valve replacement surgery. Percutaneous Valve repair is also being developed for mitral regurgitation. Direct leaflet repair and Percutaneous annuloplasty are being employed in clinical trials. All the Percutaneous approaches are based on existing surgical techniques and offer less invasive alternatives. The era of Percutaneous Valve therapy has clearly arrived, and ongoing trials will define the clinical role for these new therapies.
-
Percutaneous Valve therapies
Current treatment options in cardiovascular medicine, 2005Co-Authors: Howard C. HerrmannAbstract:Recent innovations have occurred in the treatment of valvular heart disease so that we now stand at the very beginning of a field that is likely to show considerable growth in the future. These innovations include the introduction of self-expanding and balloon-expandable stents containing bioprosthetic heart Valves, and other valvular implants and techniques for the repair and treatment of valvular heart disease. Previously, the field of nonsurgical cardiac Valve repair and replacement consisted solely of the use of balloon valvuloplasty for valvular stenosis. The ability to address aortic stenosis more definitively than with balloon valvuloplasty and to address regurgitant Valve lesions will greatly expand the patients who can be treated without surgery. Percutaneous Valve repair and replacement is at an early stage with a variety of techniques that are undergoing investigation. Similar to the initial development of balloon angioplasty for coronary artery disease, improvements in technology, techniques, and experience will be necessary before we can reproduce the excellent results achieved today with surgery.
-
Percutaneous Valve Replacement for Aortic Stenosis
NEJM Journal Watch, 2004Co-Authors: Howard C. HerrmannAbstract:Surgical aortic-Valve replacement relieves symptoms and prolongs survival in patients with critical aortic stenosis. Researchers in France and the U.S.
-
Percutaneous Valve repair and placement.
The Journal of invasive cardiology, 2004Co-Authors: Howard C. HerrmannAbstract:The treatment of valvular heart disease has progressed markedly in the past 20 years. Though Percutaneous Valve procedures are not nearly as widely performed as coronary intervention today, the emergence of new procedures for Percutaneous Valve repair and replacement indicates that this field is on the brink of rapid progression, just as angioplasty was approximately 20 years ago.